Legend Innovation Life Science Fund has announced a commitment of up to $50 million in funding for Mid-Atlantic BioTherapeutics (MABT), a clinical-stage biotech firm based in Pennsylvania. The investment marks a significant milestone for MABT, which has been steadily building a reputation for its pioneering work in anti-aging therapies, with a particular focus on neurological diseases and cancer.
Legend Innovation is no stranger to transformative science. Known for backing companies that harness AI to accelerate drug discovery, the fund has carved out a niche in identifying and supporting biotech ventures poised for rapid growth and public market success. Its strategy centers on investing in pre-IPO companies that are not only scientifically compelling but also commercially viable, with clear pathways to regulatory approval and market entry.
The partnership with MABT reflects Legend’s confidence in the company’s scientific vision and leadership. MABT has developed a robust pipeline of therapeutic candidates, including a promising drug for viral encephalitis that is expected to enter Phase 3 clinical trials in 2026. The company’s approach to drug development is deeply rooted in computational chemistry and structure-based design, leveraging AI to identify and optimize molecular fragments with high therapeutic potential. This platform enables MABT to move swiftly from concept to clinic, reducing the time and cost typically associated with traditional drug development.
The first tranche of Legend’s investment is scheduled to be deployed in the third quarter of 2025. These funds will be used to advance MABT’s clinical programs, support ongoing research initiatives, and help the company meet key regulatory milestones. In addition to its lead candidate, MABT is actively expanding its pipeline with new programs that target age-related degeneration and chronic diseases—areas where traditional therapies have often fallen short.
Looking ahead, MABT is preparing for a potential public listing, either through a traditional IPO or a reverse merger, within the next 18 months. This move would not only provide additional capital for growth but also position the company as a publicly traded leader in the emerging field of AI-driven anti-aging therapeutics.
The collaboration between Legend and MABT is more than just a financial transaction—it’s a strategic alignment of values and vision. Both organizations are committed to pushing the boundaries of what’s possible in biotechnology, and together, they aim to set new standards for innovation, efficiency, and impact.
KEY QUOTES:
“Our dedication to transformative healthcare innovation is reflected in this partnership with Mid-Atlantic BioTherapeutics. MABT’s scientific vision and strong leadership make them an ideal investment for our fund as we work to rapidly translate pioneering research into real-world therapies for patients in need.”
Dr. Syngbum (Ben) Kim, Chairman and Founder of Legend
“We are honored by Legend’s confidence in our technology and mission. This strategic investment will enable us to accelerate our programs targeting various aspects of anti-aging. With Legend’s support, we are positioned to accelerate our programs that aim to extend the length and quality of people’s lives.”
Dr. David Horn, CEO and Founder of Mid-Atlantic BioTherapeutics
